Tiefeng Xu

机构：First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University

发表论文 19 篇 · 总被引 141 次 · h-index 7

代表论文

• The adenosine analog prodrug ATV006 is orally bioavailable and has preclinical efficacy against parental SARS-CoV-2 and variants (2022 · Science Translational Medicine · 被引 44)
• Synthesis of deuterated S-217622 (Ensitrelvir) with antiviral activity against coronaviruses including SARS-CoV-2 (2023 · Antiviral Research · 被引 19)
• Preclinical characterization and anti-SARS-CoV-2 efficacy of ATV014: an oral cyclohexanecarboxylate prodrug of 1′-CN-4-aza-7,9-dideazaadenosine C-nucleoside (2023 · Signal Transduction and Targeted Therapy · 被引 14)
• Comparison of model‐specific histopathology in mouse models of COVID‐19 (2022 · Journal of Medical Virology · 被引 12)
• The Impact of Accumulated Mutations in SARS-CoV-2 Variants on the qPCR Detection Efficiency (2022 · Frontiers in Cellular and Infection Microbiology · 被引 11)
• A comprehensive evolutionary and epidemiological characterization of insertion and deletion mutations in SARS-CoV-2 genomes (2021 · Virus Evolution · 被引 10)